Investors are advised to be aware of clues given by a biotechnology company’s financial reports before they invest in the highly unpredictable sector, experts said at a forum yesterday.
Growth prospects, technical capacity, and capital reserves are the main factors to consider in assessing the viability of investing in a biotechnology company, PricewaterhouseCoopers (PwC) Taiwan deputy chairman Audrey Tseng (曾惠瑾) said.
Growth prospects encompasses the business model of a company, and the terms it has established with its distributors that determine licensing schemes and milestone payments upon regulatory approval and reaching of sales targets, Tseng said
Regarding technical capacity, Tseng said that a new drug development company’s prospects can often been seen in its expenditure.
“We assess the rate of growth of research & development expenditure, and its proportion in relations to operating costs and consolidated revenues,” Tseng said.
A biotechnology firm’s survival depends on its cash reserves, she said.
In the event of a failed clinical trial, a company with ample cash might be able to bide its time and continue its research, while its cash-strapped peer perishes, she said.
“We also calculate the number of years a company might be able to continue operating in the black,” Tseng said, adding that she has found levels of cash reserves in the sector to be adequate.
Companies become defenseless when they have ran out of cash, and might have to turn over their unfinished work at bargain prices as their operations go into the red, she said, adding that a number of new drugs developed by Taiwanese companies are based on compounds acquired from foreign companies.
Tseng said that taxes on stock options remains a tremendous challenge for the sector.
In light of the lower salary for key researchers, companies often grant stock options, she added.
However, taxes are due upon the purchase of the new shares, and the expense adds to financial losses by researchers when the shares of their company swings wildly, she said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day